home / stock / konef / konef news

KONEF News and Press, KetamineOne Capital Limited From 03/09/23

Stock Information
Company Name: KetamineOne Capital Limited
Stock Symbol: KONEF
Market: OTC
Website: wellbeingdigital.co
Menu
KONEF KONEF Quote KONEF Short KONEF News KONEF Articles KONEF Message Board
Get KONEF Alerts

News, Short Squeeze, Breakout and More Instantly...
KONEF - Wellbeing Digital to Participate in The Global Biomedical Design Conference

Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychede...
KONEF - Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout

The company has received approval to proceed with the buildout of a level 5 security system at its state-of-the-art research facility in London Ontario Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) ...

KONEF - Wellbeing Digital to Participate in MarigoldLIVE: International Women's Day Networking Event

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...

KONEF - Wellbeing Provides Bi-Weekly Default Status Report

Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ) is providing this update with respect to the management cease trade order (“ MCTO ”) issued by the British Columbia Securitie...
KONEF - Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.

New study outlines the safety profile of a novel, naturally-occurring methylxanthine compound (paraxanthine) in foods and provides a direct head-to-head comparison between paraxanthine Px and caffeine. Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Com...

KONEF - Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial

A section 56 exemption can enable an approved medical professional to prescribe select controlled substances without legal consequence, in order to better treat people with otherwise treatment-resistant conditions. Wellbeing Digital Sciences Inc. (“ Wellbeing” or the &#x...

KONEF - Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order

Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychede...
KONEF - Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...

KONEF - Wellbeing Digital Announces Change of Auditor

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...

KONEF - Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial

KGK has received approval from Health Canada for Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), a...
Previous 10 Next 10